How to dose semaglutide

The standard titration of semaglutide (Semaglutide) runs through 0.25 mg a week for the first four weeks and then moves on to 0.5 mg, 1.0 mg, 1.7 mg and 2.0 mg at four-week intervals, with each step held for a minimum of 28 days before going up to the next one. For research subjects with gastrointestinal sensitivity, a slow-titration variant published in Diabetes Care (2025) raised the dose every week in fine increments instead of taking stepped jumps in milligrams, and it achieved better persistence than the standard escalation did, because the gradual approach allows a greater degree of gastric adaptation to take place [4].

Further down on this page you will find the full protocol together with the slow-titration variant.

Semaglutide is not part of Body Pharm's catalogue for Spain: this guide treats it purely as a reference compound.

Semaglutide dosing: the essentials

• Semaglutide is titrated over the course of 16–24 weeks according to gastrointestinal tolerability, starting at 0.25 mg and going up to a weekly ceiling of 2.0 mg
• Each dose step has to be held for a minimum of 28 days so that steady-state plasma concentrations are reached and gastric adaptation takes place
• The slow-titration variant (doubling the 0.25 mg phase to eight weeks) improves tolerability in subjects with gastrointestinal sensitivity without any loss of efficacy
• Rotating the injection sites and storing at 2–8 °C are decisive for the stability of the active substance throughout the whole of the titration series
• Nausea and gastrointestinal symptoms are transient in most subjects; holding the current dose for a further four weeks, rather than stepping back, usually resolves the tolerability problems

What semaglutide is and how it works

Semaglutide is a long-acting agonist of the GLP-1 (glucagon-like peptide-1) receptor, with a molecular weight of 4,113.58 Da and an elimination half-life of around 165–184 hours. That half-life is the pharmacokinetic basis for weekly subcutaneous dosing; it allows a predictable accumulation of steady-state plasma concentrations from injections that are given once a week.

The molecule itself is a 31-amino-acid analogue of native GLP-1, structurally modified with a C18 fatty diacid chain that mediates binding to albumin and prolongs the systemic exposure.

Agonism at the GLP-1 receptor produces three effects that are relevant to the dosing models used in research:

• Glucose-dependent insulin secretion by the β-cells of the pancreas
• Delayed gastric emptying (the dominant driver of the gastrointestinal adverse-effect profile that justifies slow titration)
• Central modulation of appetite through the GLP-1 receptors in the arcuate nucleus of the hypothalamus

The third pathway is the one that underlies the weight-loss end points observed in the STEP series of studies (2021–2023), because GLP-1 signalling in the hypothalamus reduces the hunger signals.

Why the half-life sets the pace of titration

Steady-state plasma concentrations are reached after around four to five half-lives, which is to say at 28–35 days. That calculation explains why each step in the tirzepatide dosing protocol and in the comparable escalation models in Retatrutide vs semaglutide vs tirzepatide is held for a minimum of 28 days before the next increase. Each dose reaches equilibrium before the move up to the next one.

Standard semaglutide titration schedule (0.25–2 mg)

The canonical weekly titration schedule for semaglutide escalates in five fixed phases: 0.25 mg in weeks 1–4, 0.5 mg in weeks 5–8, 1 mg in weeks 9–12, 1.7 mg in weeks 13–16 and 2.0 mg from week 17 onwards. Each of the steps is held for a minimum of 28 days. The ladder below reflects the titration steps of STEP 1 (Wilding et al., NEJM, 2021) [1], with the ceiling set at the 2.0 mg authorised in the Ozempic SmPC [2]; the maintenance arm of STEP 5 (Garvey et al., Nature Medicine, 2022) confirmed the tolerability of the 2.4 mg dose over 104 weeks of continuous administration [5]; no dose-limiting toxicity appeared during that extended period.

Why each phase is held for four weeks

Holding each dose for 28 days serves two distinct pharmacological functions. First: it allows the plasma concentrations to approach equilibrium before the next stimulus is applied; with a half-life of 165–184 hours, tolerability can be assessed accurately at that equilibrium. Second: it allows tachyphylaxis to develop at the level of gastric emptying, which is the tolerability factor that sets the pace. The delayed-emptying effect attenuates with sustained exposure and reduces the incidence of nausea at the next move up, because the digestive system adapts to the effect.

Some research subjects are concerned that holding a dose for four weeks delays progress towards the therapeutic end point. In practice, accelerating the phases increases the risk of an intolerance that forces a dose reduction or a discontinuation, and that delays progress far more than a cautious titration ever does.

The 2 mg ceiling

2.0 mg a week is the maximum dose authorised in the Ozempic SmPC [2]; the STEP programme validated 2.4 mg a week as the registration dose for Wegovy [1][3]. STEP 5 showed that the 2.4 mg dose can be maintained for two years in the majority of participants without any dose reduction [5]; with higher exposures there were no additional safety signals and no additional efficacy gains. Going beyond 2 mg in the research model brings no additional documented benefit in terms of receptor occupancy, and it raises the burden of gastrointestinal adverse effects disproportionately, because the higher concentrations accentuate the delayed gastric emptying. For the within-class comparison, see Retatrutide vs semaglutide vs tirzepatide and the parallel ladder in Tirzepatide dosing.

Extended slow-titration variant for cases of gastrointestinal sensitivity

The slow-titration variant holds 0.25 mg a week for eight weeks instead of four, and then it follows the standard ladder from there. The total time to reach 2 mg goes from 16 weeks to around 20–24. This trades speed for tolerability, and it is what is indicated when a research subject reports persistent nausea, early satiety below a functional level of food intake, or vomiting at the standard move up in week 5; those symptoms signal insufficient gastric adaptation.

The mechanistic rationale behind it is gastric tachyphylaxis. The delayed-emptying effect, which causes most of the upper digestive symptoms, attenuates with continued exposure. Doubling the conditioning window gives that adaptation more room before the first therapeutic step. A report in Diabetes Care (2025) on gradual titration (going up every week in fine increments until the target dose is reached) found better persistence than with the standard escalation [4]. It is the closest published proxy to the slow-titration logic that is applied here, because both approaches prioritise a gradual activation of the receptors over a rapid escalation. There is currently no published head-to-head comparison of the incidence of nausea between an 8-week hold at 0.25 mg and the standard 4-week hold. The STEP 1 observation (2021), with an incidence of nausea of 44.2% with standard titration [1], is relevant from a mechanistic point of view, but it predates the randomised pilot trial on gradual titration [4].

Some subjects are concerned that holding the starting dose for eight weeks will produce no therapeutic effect at all. The 0.25 mg phase is deliberately sub-therapeutic; holding it for longer lets the digestive system adapt without the confounding variable of rising doses, and it makes the move to 0.5 mg (the first therapeutic step) far more tolerable.

Modified slow-titration schedule

When to depart from the schedule even further

If the gastrointestinal symptoms reappear with the move up to 0.5 mg in week 9, hold the dose rather than stepping back. Going back to 0.25 mg after eight weeks of exposure rarely improves tolerability; the digestive system has already begun to adapt to the effect, and stepping back resets that adaptation. Instead, extend the 0.5 mg phase to eight weeks and then continue up the ladder afterwards. For anyone running parallel protocols with GLP-1 agents, the same principle of holding rather than stepping back is described in the Tirzepatide dosing ladder, and the tolerability profiles of the whole class are summarised in the Retatrutide vs semaglutide vs tirzepatide comparison.

This variant is a deviation from the registration schedule and it should be documented as such in any laboratory protocol.

Subcutaneous injection technique and site rotation

There are three validated subcutaneous sites for the administration of semaglutide: the abdomen (a minimum of 5 cm from the navel), the front of the thigh and the back of the upper arm. Rotating between them in successive weeks reduces the risk of lipohypertrophy, a local alteration of the subcutaneous tissue that modifies the absorption kinetics and introduces variability into the steady-state plasma profile, because injecting repeatedly into the same site can provoke a proliferation of fatty tissue.

Keep to the same day of the week throughout the whole of the titration cycle. With a terminal half-life of around seven days, weekly dosing produces steady-state plasma concentrations after around four to five weeks. Changing the injection day in the middle of the titration distorts the AUC (area under the curve) profile and confounds any assessment of tolerability, because the pharmacokinetic rhythm becomes irregular.

Some subjects are concerned that rotating the injection sites will cause inconsistent absorption. In practice, the blood supply to the subcutaneous space is uniform across the abdomen, the thigh and the arm. Rotation avoids lipohypertrophy, which causes far more variability in absorption than the choice of site does on its own.

Reported parameters for subcutaneous administration

1. Site preparation. The protocols describe cleaning the chosen site with a 70% isopropyl alcohol wipe and letting it dry for 30 seconds for antisepsis.
2. Skin fold. The usual practice is to lift a 2–3 cm fold between the thumb and the forefinger in order to separate the subcutaneous layer from the muscle.
3. Needle angle. The angles described are around 90° for the abdomen and the thigh in subjects with sufficient subcutaneous depth, and around 45° in lean subjects or in the arm, since the flatter angle is associated with a lower risk of intramuscular injection.
4. Administration speed. Pressing the plunger slowly over 5–10 seconds reportedly minimises tissue back-pressure and the formation of a weal, both of which can otherwise reduce the consistency of absorption.
5. Withdrawal. The protocols describe withdrawing the needle along the axis of entry, releasing the skin fold and pressing gently with gauze for 10 seconds; the literature advises against massaging the site, because it can alter the local blood supply and the distribution of the active substance.

Needle specification

A 29–31 G (gauge) needle of 4–8 mm in length is the standard described for the subcutaneous administration of peptides, because that gauge and that length minimise tissue trauma and reach the subcutaneous space reliably. The final choice should follow the instructions for the device that has been supplied, not a class standard deduced from elsewhere. Use a new, sterile needle for each and every injection; reusing one dulls the bevel and increases the tissue trauma at the injection site, because the blunt edge causes more mechanical damage.

Rotation scheme

A simple four-week rotation (left abdomen → right abdomen → left thigh → right thigh, keeping the arms for assisted administration) spreads the injection trauma around and favours consistent absorption, because each site has time to recover. The same rotation principle underpins the recommendations for insulin administration; the technical standard has not changed substantially since then, because the physiological rationale still holds good. For class-level dosing comparisons, see Tirzepatide dosing.

Storage, handling and stability

Semaglutide is stored at 2–8 °C, protected from light, and it is never frozen, because those conditions slow down the degradation of the peptide. The integrity of the cold chain is the single most important factor for the analytical reproducibility of a titration series, because swings in temperature accelerate chemical degradation. The in-use window after the first puncture depends on the specific product and on its SmPC [2][3].

Take the product out of the refrigerator around 30 minutes before the injection so that it reaches room temperature. A cold solution increases the discomfort felt at the injection site. Protect it from light straight after each dose in order to limit photodegradation and contamination of the rubber septum.

Discard any solution that looks cloudy or discoloured or that contains visible particles; these are signs of peptide aggregation or of microbial contamination. Temperature excursions above 30 °C accelerate the degradation of the peptide and should be recorded. A single excursion does not necessarily mean a loss of activity, but a product with an undocumented temperature history should not be used for quantitative work, because its potency cannot be verified.

Storage parameters at a glance

For class-level handling parallels between GLP-1 agonists and dual or triple agonists, see Retatrutide vs semaglutide vs tirzepatide.

How to handle the common tolerability problems during titration

The gastrointestinal tolerability problems that arise during semaglutide titration are above all nausea, vomiting, diarrhoea and constipation. They are concentrated in the first 4–8 weeks of the escalation, and in research cohorts they are usually transient, because the digestive system adapts to the delayed gastric emptying. The STEP 1 study (Wilding et al., NEJM, 2021) reported nausea in 44.2% of the semaglutide arm as against 16.0% with placebo [1], and most of the events were classed as mild or moderate and self-limiting, because the underlying mechanism (the delayed gastric emptying) attenuates over time. The 2021 dataset predates the 2023 cut-off date, but it remains the most robust incidence reference available for the 2.4 mg weekly end point.

The solution at protocol level is simple: do not raise the dose while the symptoms persist. Hold the current weekly dose for a further four weeks and then reassess. If the intolerance continues, go back for 2–4 weeks to the step that was previously tolerated before attempting the escalation again, because that gives the digestive system time to stabilise. A report in Diabetes Care (2025) on gradual titration found better persistence when the escalation was slowed down with fine increments instead of fixed monthly doublings [4]. Persistence is a proxy for tolerability; that work also reported less nausea (45.1% versus 64.2%) and fewer withdrawals due to gastrointestinal events (2% versus 19%) with the flexible titration [4].

High-fat meals and large volumes of food consistently make nausea and reflux worse in research subjects. This is down to the gastric emptying that semaglutide delays, because fat slows gastric transit even further. According to observational reports, smaller and lower-fat meals on the day of the injection and in the 48 hours that follow reduce the intensity of the symptoms, because they minimise the mechanical load on a stomach that has already been slowed.

Decision matrix for tolerability events

These are research observations drawn from controlled cohorts, not medical advice. To put tolerability into a class-level context, the Retatrutide vs semaglutide vs tirzepatide comparison and the parallel Tirzepatide dosing protocol document the distinct gastrointestinal profile of the dual agonist.

Semaglutide vs tirzepatide vs retatrutide: dosing compared

Semaglutide tops out at 2 mg a week, tirzepatide at 15 mg a week and retatrutide at 12 mg a week according to the published phase 2 data. The difference in milligrams does not reflect potency, because each peptide acts on a different combination of receptors and has a different molecular weight. Semaglutide is a GLP-1 mono-agonist, tirzepatide is a dual GLP-1/GIP (glucose-dependent insulinotropic polypeptide) agonist and retatrutide is a triple GLP-1/GIP/glucagon agonist.

The size of the dose reflects receptor binding affinity and molecular weight, not relative pharmacological potency. More milligrams do not necessarily translate into a greater biological effect. A 2 mg dose of semaglutide and a 15 mg dose of tirzepatide are not comparable units, because they act on different combinations of receptors. Each agent also has its own pace of titration. Tirzepatide escalates in 2.5 mg steps every four weeks, as against the 0.25 mg → 0.5 mg → 1.0 mg → 1.7 mg → 2.0 mg path of semaglutide, because the pharmacokinetics of the dual agonist allow larger increments.

The full comparison is in Retatrutide vs semaglutide vs tirzepatide. The parallel Tirzepatide dosing protocol documents the dual agonist's slower escalation grid and its lower reported rate of gastrointestinal events at an equivalent percentage of the maximum dose, because GIP agonism may modulate some of the gastric effects that are driven by GLP-1 alone.

Frequently Asked Questions

Frequently asked questions on semaglutide titration, answered solely with the research context in mind.

Can a weekly dose be skipped?

Skipping a single dose does not require the titration to be started again from the beginning, because semaglutide's 165-hour half-life means that one omitted injection does not appreciably alter the steady-state plasma concentrations. If more than two consecutive weeks are missed, go down one titration step when resuming in order to avoid a gastrointestinal rebound, because the body has partially eliminated the active substance and re-escalating can provoke tolerability problems.

What happens if an injection is missed?

Give the missed dose within the 5 days following the scheduled day and continue with the original weekly plan, because that window preserves the pharmacokinetic rhythm [3]. If more than 5 days have passed, skip that dose entirely and inject on the next scheduled day, because a late injection would create an irregular dosing pattern. No double doses to make up for the one that was missed; semaglutide's 165-hour half-life makes catch-up doses pharmacokinetically meaningless, because the previous dose is still circulating.

Can the dose be split across the week?

Splitting it up is not supported by the dosing data from the STEP programme, which used single weekly injections throughout, because the long half-life is designed for once-weekly administration. Twice-weekly microdosing is an editorial protocol variant, not a validated schedule. The 165-hour half-life produces stable plasma levels from a single weekly injection, so splitting it provides no kinetic advantage, because the active substance accumulates to the same steady-state concentration whether it is given in one dose or in two smaller ones.

Is 2 mg the maximum dose in research protocols?

Yes, 2 mg a week is the ceiling of this protocol's ladder and the maximum dose authorised in the Ozempic SmPC [2]; the highest dose studied in the STEP programme was 2.4 mg a week, the registration dose for Wegovy [1][3]. Doses above 2.4 mg have no published efficacy or safety dataset behind them and fall outside the titration grid described in this protocol, because the registration studies have not evaluated higher exposures.

Can semaglutide be mixed with other peptides in the same injection?

No. There are no published compatibility, stability or pharmacokinetic data of any kind for co-injection with tirzepatide, retatrutide or other peptides, because the formulations were not developed to be given together. The excipient buffers and the pH differ between formulations and can precipitate or degrade the active substance, because peptides are sensitive to changes in pH and in ionic strength. For the dosing comparison, see Retatrutide vs semaglutide vs tirzepatide and Tirzepatide dosing.

Next steps

Research protocols usually start out with the standard schedule if there is no prior history of gastrointestinal sensitivity; if tolerability problems are expected, or nausea has been reported with other GLP-1 agents, the slow-titration variant from week 1 is the alternative that is described. The standard practice is to document the chosen protocol in the laboratory notebook, to keep a consistent injection time with site rotation and to keep a close watch on the storage conditions. If tolerability problems arise, the decision matrix in the section on common tolerability problems applies, where holding rather than stepping back is the approach described. For cross-class comparisons, or for parallel tirzepatide dosing, see the Retatrutide vs semaglutide vs tirzepatide guide.

Sources

1. Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021. pubmed.ncbi.nlm.nih.gov/33567185
2. EMA, EPAR and summary of product characteristics (SmPC) for Ozempic (semaglutide, up to 2 mg): posology and escalation. ema.europa.eu
3. EMA, EPAR and summary of product characteristics (SmPC) for Wegovy (semaglutide 2.4 mg): posology, escalation, missed doses and storage. ema.europa.eu
4. Eldor R, et al. Gradual Titration of Semaglutide Results in Better Treatment Adherence and Fewer Adverse Events: A Randomized Controlled Open-Label Pilot Study Examining a 16-Week Flexible Titration Regimen Versus Label-Recommended 8-Week Semaglutide Titration Regimen. Diabetes Care. 2025;48(9):1607-1611. pubmed.ncbi.nlm.nih.gov/40673973
5. Garvey WT, et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med. 2022;28(10):2083-2091. pubmed.ncbi.nlm.nih.gov/36216945
6. Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022. pubmed.ncbi.nlm.nih.gov/35658024
7. Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023. pubmed.ncbi.nlm.nih.gov/37366315